secwatch / observer
8-K filed October 22, 2025, 7:59 PM ET ticker IXHL CIK 0001873875
other material confidence high sentiment neutral materiality 0.60

Incannex Healthcare gets Nasdaq bid price compliance extension to April 20, 2026

Incannex Healthcare Inc.

item 3.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-25-100980
form_type
8-K
ticker
IXHL
cik
0001873875
company_name
Incannex Healthcare Inc.
filed_at
2025-10-22T23:59:59+00:00
discovered_at
2026-05-14T18:02:40.937500+00:00
generated_at
2026-05-17T02:49:11.489499+00:00
sec_items
["3.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-25-100980
json_url
https://secwatch.observer/filing/0001213900-25-100980.json
markdown_url
https://secwatch.observer/filing/0001213900-25-100980.md
text_url
https://secwatch.observer/filing/0001213900-25-100980.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/ea0262074-8k_incannex.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

aceb532c5c26121896006e2d89fec70e39bc30d2

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)).

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

SEC 8-K Item 3.01 confidence 0.82 SEC evidence

Comparable filings

TNON

Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity

Tenon Medical, Inc. May 22, 2026, 5:15 PM ET other_material Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 21, 2026, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying the Company that it is no longer in compliance with the

Filing page SEC filing

ISPC

iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance

iSpecimen Inc. May 13, 2026, 5:00 PM ET other_material Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026

Filing page SEC filing

HUMA

Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply

Humacyte, Inc. May 8, 2026, 7:59 PM ET other_material Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, th

Filing page SEC filing

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

LIMN

Liminatus Pharma receives Nasdaq delisting notice; appeals filed

Liminatus Pharma, Inc. May 27, 2026, 4:30 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark

Filing page SEC filing

EMAT

Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved

Evolution Metals & Technologies Corp. May 26, 2026, 5:28 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 21, 2026, Evolution Metals & Technologies Corp. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that

Filing page SEC filing

AGAE

AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K

Allied Gaming & Entertainment Inc. May 21, 2026, 9:40 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

May 19, 2026, All In FutureTech Alliance, Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of

Filing page SEC filing

PMI

Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices

Picard Medical, Inc. May 21, 2026, 4:15 PM ET other_material Items 2.02, 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material

This filing

April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period

Comparable filing

reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-25-100980
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.